2,347 results on '"Felker, G"'
Search Results
102. Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials
103. Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial
104. Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF
105. Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan
106. Predictors of early dyspnoea relief in acute heart failure and the association with 30‐day outcomes: findings from ASCEND‐HF
107. Circulating T-Cell Subsets, Monocytes, and Natural Killer Cells in Peripartum Cardiomyopathy: Results From the Multicenter IPAC Study
108. Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF
109. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study.
110. Relaxin, a pleiotropic vasodilator for the treatment of heart failure
111. Managing Obesity in Heart Failure
112. Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart Failure
113. Blood Volume Analysis-Guided Heart Failure Management
114. Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study
115. Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial
116. Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19
117. Serum Proteomic Analysis of Peripartum Cardiomyopathy Reveals Distinctive Dysregulation of Inflammatory and Cholesterol Metabolism Pathways
118. Importance of the ‘area under the curve’ from serial NT‐proBNP measurements during treatment with sacubitril/valsartan
119. Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study
120. Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network)
121. Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from DOSE-AHF and ROSE-AHF)
122. Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial
123. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure
124. Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction
125. Contributors
126. Preface
127. Heart Failure as a Consequence of Ischemic Heart Disease
128. Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial
129. Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study
130. Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
131. Racial Differences in Serial NT-proBNP Levels in Heart Failure Management: Insights From the GUIDE-IT Trial
132. Heart Failure Clinical Trial Operations During the COVID-19 Pandemic: Results From a Multicenter Survey
133. Challenges and Potential Improvements to Patient Access to Pharmaceuticals: Examples From Cardiology
134. Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction
135. Biomarkers in Advanced Heart Failure: Implications for Managing Patients With Mechanical Circulatory Support and Cardiac Transplantation
136. Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure
137. Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial
138. Decongestion Strategies for Ambulatory Outpatients
139. Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure
140. Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan
141. Echocardiographic Features Beyond Ejection Fraction and Associated Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
142. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
143. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure
144. Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group
145. Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial
146. Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study
147. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study
148. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial
149. Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?
150. Cardiac transplantation for older patients: Characteristics and outcomes in the septuagenarian population
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.